CRISPR gene-editing approved for first human trials

Share

A federal ethics and biosafety panel has approved the first human trials using CRISPR-Cas9. Researchers at UPenn will remove immune system T cells from up to 15 patients with multiple melanoma, melanoma, and sarcoma. The cells will be modified to fight malignant cells normally, then reinserted into the patient.

 

CRISPR-Cas9 genome editing has never been tried on humans, so early studies will focus on safety and efficacy. These trials will be funded by the Parker Institute for Cancer Immunotherapy. Researchers still need approval from the FDA and hospitals conducting the studies – MD Anderson Cancer Center in Texas, USC San Francisco and Penn – before they begin.

 

Read the original article at engadget.com…

 

Share

Comments are closed.